Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Arthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Revenue Service

Lannett Company
Posted on: 25 Sep 17

PHILADELPHIA, Sept. 22, 2017 /PRNewswire/ -- Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). 

Bedrosian filed a lawsuit against the IRS, after the IRS claimed Bedrosian failed to properly and timely report a foreign bank account, which he opened in 1973.  The IRS filed a counterclaim, seeking payment of a penalty, plus interest totaling $1,007,346.  After a one day trial, Senior United States District Judge for the Eastern District of Pennsylvania, Michael M. Baylson, found that Bedrosian was credible and that he did not willfully fail to identify one of two foreign accounts on a Report of Foreign Bank and Financial Accounts, which he filed in 2008.  The Court also found that the IRS had illegally extracted the sum of $9,758 from Bedrosian.  The Court thus entered judgment in favor of Bedrosian and against the IRS in the amount of $9,758 and in favor of Bedrosian and against the IRS on the IRS' counterclaim.

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company's website at


Robert Jaffe


Robert Jaffe Co., LLC


(424) 288-4098

Editor's Details

Mike Wood

Last updated on: 25/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.